A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 52, 2011, Pages 21052-21056

  Schiering, Nikolaus ^a   D'Arcy, Allan ^a   Villard, Frederic ^a   Simić, Oliver ^a   Kamke, Marion ^a   Monnet, Gaby ^a   Hassiepen, Ulrich ^a   Svergun, Dmitri I ^b   Pulfer, Ruth ^a   Eder, Jörg ^a   Raman, Prakash ^c   Bodendorf, Ursula ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b DESY   (Germany)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Medicinal chemistry; Solution scattering; Structure based drug design; X ray structure

Indexed keywords

ANTIVIRUS AGENT; HELICASE; PROTEINASE; PROTEINASE INHIBITOR; VIRUS ENZYME;

ARTICLE; CRYSTAL STRUCTURE; DRUG STRUCTURE; HEPATITIS C VIRUS; IC 50; PRIORITY JOURNAL; PROTEIN DOMAIN; X RAY CRYSTALLOGRAPHY;

CARRIER PROTEINS; CHROMATOGRAPHY, GEL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; HEPATITIS C; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; PROTEASE INHIBITORS; PROTEIN CONFORMATION; SCATTERING, SMALL ANGLE; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84855504864     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1110534108     Document Type: Article

References (36)

1. Melnikova I (2011) Hepatitis C - pipeline update. Nat Rev Drug Discovery 10:93-94.
2. Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8:257-264.
3. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO (1995) Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 69:7519-7528.
4. Brass V, et al. (2008) Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci USA 105:14545-14550.
5. Taremi SS, et al. (1998) Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 7:2143-2149. (Pubitemid 28495801)
6. Gale M, Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436:939-945.
7. Beran RK, Serebrov V, Pyle AM (2007) The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J Biol Chem 282:34913-34920. (Pubitemid 350232430)
8. Beran RK, Pyle AM (2008) Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem 283:29929-29937.
9. Kim JL, et al. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355. (Pubitemid 26359011)
10. Love RA, et al. (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342. (Pubitemid 26359010)
11. Cummings MD, et al. (2010) Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl 49:1652-1655.
12. Romano KP, Ali A, Royer WE, Schiffer CA (2010) Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci USA 107:20986-20991.
13. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353-1363. (Pubitemid 29529876)
14. Appleby TC, et al. (2011) Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV. J Mol Biol 405:1139-1153.
15. Ding SC, Kohlway AS, Pyle AM (2011) Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus. J Virol 85:4343-4353.
16. Dahl G, Sandström A, Akerblom E, Danielson UH (2007) Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3. FEBS J 274:5979-5986. (Pubitemid 350045808)
17. Thibeault D, et al. (2009) Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A. Biochemistry 48:744-753.
18. Liverton NJ, et al. (2008) Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J Am Chem Soc 130:4607-4609. (Pubitemid 351500096)
19. Luo D, et al. (2008) Crystal structure of the NS3 protease-helicase from dengue virus. J Virol 82:173-183. (Pubitemid 350309134)
20. Luo D, et al. (2010) Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem 285:18817-18827.
21. Assenberg R, et al. (2009) Crystal structure of a novel conformational state of the flavivirus NS3 protein: Implications for polyprotein processing and viral replication. J Virol 83:12895-12906.
22. Bollati M, et al. (2010) Structure and functionality in flavivirus NS-proteins: Perspectives for drug design. Antiviral Res 87:125-148.
23. Mastrangelo E, et al. (2007) Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full-length NS3 protein. J Mol Biol 372:444-455. (Pubitemid 47267949)
24. Tsantrizos YS, et al. (2003) Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed 42:1356-1360. (Pubitemid 36459971)
25. Shawn B, et al. (2008) Macrocyclic compounds as HCV NS3 protease inhibitors. US Patent WO2008101665.
26. D'Arcy A, Villard F, Marsh M (2007) An automated microseed matrix-screening method for protein crystallization. Acta Crystallogr D63:550-554. (Pubitemid 46465951)
27. Kroemer M, Dreyer MK, Wendt KU (2004) APRV - a program for automated data processing, refinement and visualization. Acta Crystallogr D60:1679-1682. (Pubitemid 41103555)
28. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D60:2126-2132. (Pubitemid 41742764)
29. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D53:240-255. (Pubitemid 27235885)
30. Bricogne G, et al. (2010) BUSTER. (Global Phasing Ltd., Cambridge, UK) Version 2.9.
31. Lee B, Richards FM (1971) The interpretation of protein structures: Estimation of static accessibility. J Mol Biol 55:379-400.
32. Roessle MW, et al. (2007) Upgrade of the small angle X-ray scattering beamline X33 at the European Molecular Biology Laboratory, Hamburg. J Appl Crystallogr 40:190-194.
33. Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI (2003) PRIMUS - a Windows-PC based system for small-angle scattering data analysis. J Appl Crystallogr 36:1277-1282.
34. Svergun DI (1992) Determination of the regularization parameter in indirecttransform methods using perceptual criteria. J Appl Crystallogr 25:495-503.
35. Svergun DI, Barberato C, Koch MHJ (1995) CRYSOL - a program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates. J Appl Crystallogr 28:768-773. (Pubitemid 3014671)
36. DeLano WL (2002) The PyMOL Molecular Graphics System . (DeLano Scientific, San Carlos, CA).